Physician profile

Adnan Nasir

Dermatology · Raleigh, NC

NPI 1457429706

$126.96

in general payments reported to CMS, 2019-2025

15 companies · none reported in 2025

See the full distribution for Dermatology

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$16.80

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $51.18 2020-2021
Abbvie INC. $22.02 2021
Merck Sharp & Dohme LLC $20.63 2019
Incyte Corporation $16.80 2023
Actelion Pharmaceuticals US, INC. $16.33 2019

10 companies reported research payments only; those appear in the research section below.

Research and ownership

$4,686.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Adnan Nasir

$126.96

in general payments reported 2019-2025

Years
2019-2023
Top company
Eli Lilly and Company

https://glasscript.com/doctor/338704/adnan-nasir

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.